Intensity-modulated radiotherapy (IMRT)

RADIATION10 trials

Sponsors

Department of Radiation Oncology, Gunma University Graduate School of Medicine, Sidney Kimmel Cancer Center at Thomas Jefferson University, University of Michigan Rogel Cancer Center, Dana-Farber Cancer Institute, Hubei Cancer Hospital

Conditions

Anal Squamous Cell Carcinoma, Limited-stageCancer of NasopharynxCarcinoma of LarynxCarcinoma, Squamous Cell of Head and NeckEarly Invasive Cervical Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaHPV Positive Oropharyngeal Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma

Phase 1

Using Intensity Modulated Radiation Therapy (IMRT) for Brain Metastases

CompletedNCT00328575

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNeoplasm Metastasis

Start: 2005-10-31End: 2011-06-30Updated: 2016-10-21

Dose escalation study of intensity-modulated radiotherapy (IMRT) for ipsilateral intrathoracic recurrence after pneumonectomy (lung cancer/mediastinal tumor) or mesothelioma after extrapleural pneumonectomy

Active, not recruitingJPRN-UMIN000004066

Department of Radiation Oncology, Gunma University Graduate School of MedicineRecurrence of thoracic malignancy (lung cancer/mediastinal tumor), or mesothelioma

Start: 2010-08-01Target: 9Updated: 2026-06-29

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

CompletedNCT02113878

Dana-Farber Cancer InstituteCancer of Nasopharynx, Carcinoma of Larynx, Carcinoma, Squamous Cell of Head and Neck +3

Start: 2014-09-29End: 2022-01-01Updated: 2024-11-05

Phase 2

A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients

CompletedNCT01661088

University of Michigan Rogel Cancer CenterPancreatic Cancer

Start: 2011-06-30End: 2019-08-30Updated: 2019-11-13

Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin

CompletedNCT02562599

Hubei Cancer HospitalNasopharyngeal Carcinoma

Start: 2015-08-31End: 2018-08-31Updated: 2022-02-22

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

CompletedNCT05213884

Chongqing University Cancer HospitalHead and Neck Squamous Cell Carcinoma

Start: 2022-01-01End: 2026-02-08Updated: 2026-04-24

Efficacy of Lenalidomide Maintenance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma: a Phase II, Open-label, Single-arm Study

Not yet recruitingNCT05901324

National Taiwan University HospitalPrimary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma

Start: 2023-07-01End: 2031-05-31Target: 20Updated: 2023-06-13

Phase 3

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

RecruitingNCT05919030

Renmin Hospital of Wuhan UniversityEsophageal Squamous Cell Carcinoma

Start: 2023-07-01End: 2027-07-01Target: 155Updated: 2024-11-14

Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma

RecruitingNCT07000643

Man HuNasopharyngeal Carcinoma

Start: 2025-05-07End: 2029-02-28Target: 386Updated: 2025-06-03

Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma

RecruitingNCT07692152

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAnal Squamous Cell Carcinoma, Limited-stage

Start: 2026-03-17End: 2029-03-01Target: 350Updated: 2026-07-09

Related Papers

The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells.

2020-10-0119 citations

Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.

2019-09-0531 citations

A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN).

Journal of Clinical Oncology2018-05-206 citations

Neoadjuvant FOLFIRINOX and IMRT concurrent with FDR-gemcitabine in patients with borderline resectable pancreatic cancer (BRPC).

Journal of Clinical Oncology2018-02-014 citations